10/20/2025 | Press release | Archived content
Durham, NC - [October 20, 2025] - BioAgilytix, the global leader in bioanalysis, has advanced its growth strategy with multi-million-dollar investments in Liquid Chromatography-Mass Spectrometry (LC/MS) capabilities, including new platforms and expanded lab space in Hamburg, Germany and Durham, North Carolina. BioAgilytix is reinforcing its position as the trusted partner for biopharmaceutical sponsors developing next-generation therapeutics.
Strategic Investments
Unified Assay Oversight
"Dave Beyerlein, Global Lead for LC/MS oversees platform and process harmonization globally and seamless assay transfers from lab to lab, while maintaining regulatory compliance and data integrity," said Davide Molho, CEO of BioAgilytix.
"LC/MS is critical to supporting the most innovative therapeutics," said Dave Beyerlein, Global Lead for LC/MS. "By harmonizing our platforms and processes, we ensure that our customers can move assays efficiently between sites and trust that the same standards of excellence are maintained across regions."
Global Footprint, Local Resources
With expanded capacity in the U.S., Europe, and Australia, BioAgilytix now offers a comprehensive LC/MS portfolio supporting our customers' programs across phases and modalities, globally.
Customer Benefits:
To learn more about BioAgilytix's LC/MS capabilities, visit: https://www.bioagilytix.com/techniques/assay-services/mass-spectrometry-assay/
About BioAgilytix
BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC analytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.